MCC
ASND icon

Money Concepts Capital’s Ascendis Pharma A/S ASND Stock Holding History

Money Concepts Capital’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$122 – 619
2022
Q4 		$122 Buy
+1
New +$116 ﹤0.01% 3139
2022
Q2 		– Sell
-1
Closed – – 1505
2022
Q1 		$0 Buy
+1
New +$116 ﹤0.01% 2665

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Money Concepts Capital's ASND Position: Q1 2023 in Review

Money Concepts Capital sold out of Ascendis Pharma A/S (ASND) in Q1 2023, closing a stake of 1 share — an estimated $122 sold.

Money Concepts Capital first reported a position in ASND in Q1 2022 and held it in 2 quarters. The position peaked at $122 in Q4 2022. 164 funds tracked by Wall St. Rank hold ASND as of Q1 2023.

  • Money Concepts Capital reported no remaining Ascendis Pharma A/S position as of Q1 2023 after selling out during the quarter.
  • Money Concepts Capital sold 1 Ascendis Pharma A/S share in Q1 2023, an estimated $122.
  • Money Concepts Capital first reported a position in Ascendis Pharma A/S in Q1 2022 and held it in 2 quarters.
  • Money Concepts Capital's Ascendis Pharma A/S position peaked at $122 in Q4 2022.
  • 164 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2023.

Based on Money Concepts Capital's 13F filing for Q1 2023, filed 1 May 2023.